JP2018510884A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510884A5
JP2018510884A5 JP2017552153A JP2017552153A JP2018510884A5 JP 2018510884 A5 JP2018510884 A5 JP 2018510884A5 JP 2017552153 A JP2017552153 A JP 2017552153A JP 2017552153 A JP2017552153 A JP 2017552153A JP 2018510884 A5 JP2018510884 A5 JP 2018510884A5
Authority
JP
Japan
Prior art keywords
substituted
arylalkyl
composition
heteroarylalkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552153A
Other languages
English (en)
Japanese (ja)
Other versions
JP6944377B2 (ja
JP2018510884A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/026127 external-priority patent/WO2016164401A1/en
Publication of JP2018510884A publication Critical patent/JP2018510884A/ja
Publication of JP2018510884A5 publication Critical patent/JP2018510884A5/ja
Priority to JP2021069815A priority Critical patent/JP2021102662A/ja
Application granted granted Critical
Publication of JP6944377B2 publication Critical patent/JP6944377B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552153A 2015-04-06 2016-04-06 グルタミナーゼの阻害剤を用いる肺がんの処置 Expired - Fee Related JP6944377B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021069815A JP2021102662A (ja) 2015-04-06 2021-04-16 グルタミナーゼの阻害剤を用いる肺がんの処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562143494P 2015-04-06 2015-04-06
US62/143,494 2015-04-06
US201562149489P 2015-04-17 2015-04-17
US62/149,489 2015-04-17
PCT/US2016/026127 WO2016164401A1 (en) 2015-04-06 2016-04-06 Treatment of lung cancer with inhibitors of glutaminase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021069815A Division JP2021102662A (ja) 2015-04-06 2021-04-16 グルタミナーゼの阻害剤を用いる肺がんの処置

Publications (3)

Publication Number Publication Date
JP2018510884A JP2018510884A (ja) 2018-04-19
JP2018510884A5 true JP2018510884A5 (https=) 2019-05-16
JP6944377B2 JP6944377B2 (ja) 2021-10-06

Family

ID=57015711

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017552153A Expired - Fee Related JP6944377B2 (ja) 2015-04-06 2016-04-06 グルタミナーゼの阻害剤を用いる肺がんの処置
JP2021069815A Withdrawn JP2021102662A (ja) 2015-04-06 2021-04-16 グルタミナーゼの阻害剤を用いる肺がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021069815A Withdrawn JP2021102662A (ja) 2015-04-06 2021-04-16 グルタミナーゼの阻害剤を用いる肺がんの処置

Country Status (13)

Country Link
US (1) US10441587B2 (https=)
EP (1) EP3280415A4 (https=)
JP (2) JP6944377B2 (https=)
KR (1) KR20170132333A (https=)
CN (1) CN107949387B (https=)
AU (1) AU2016246521B2 (https=)
BR (1) BR112017021312A2 (https=)
CA (1) CA2981762A1 (https=)
EA (1) EA035354B1 (https=)
IL (1) IL254876A0 (https=)
MX (1) MX383034B (https=)
SG (1) SG11201708153XA (https=)
WO (1) WO2016164401A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
BR112015010955A2 (pt) 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
EP3556757A1 (en) 2014-04-30 2019-10-23 Pfizer Inc Cycloalkyl-linked diheterocycle derivatives
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
WO2018039441A1 (en) * 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
WO2018165516A1 (en) * 2017-03-10 2018-09-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP7156856B2 (ja) * 2018-08-21 2022-10-19 国立大学法人富山大学 抗肥満剤
JP7188936B2 (ja) * 2018-08-21 2022-12-13 国立大学法人富山大学 抗炎症剤
WO2021076814A1 (en) * 2019-10-15 2021-04-22 Cornell University Methods of inhibiting liver-type glutaminase, gls2
US20240082158A1 (en) * 2020-05-21 2024-03-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for administering a yap1/wwrt1 inhibiting composition and a gls1 inhibiting composition
CN111514460B (zh) * 2020-05-22 2021-12-14 西安交通大学 大气压冷等离子体在抑制谷氨酰胺酶活性方面的用途及酶抑制剂
CN113956233B (zh) * 2021-10-22 2023-06-06 南方医科大学 一种酰胺类化合物或其药学上可接受的盐及其制备方法和应用
US20250288577A1 (en) * 2022-04-29 2025-09-18 Cornell University Methods of treating a virus infection and methods of inhibiting viral replication

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
KR101325374B1 (ko) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
US20120302605A1 (en) 2010-11-18 2012-11-29 Deuteria Pharmaceuticals, Llc 3-deutero-pomalidomide
CN103030597B (zh) * 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
EP2855698A4 (en) * 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
MX2015003114A (es) 2012-09-10 2015-07-06 Celgene Corp Metodos para el tratamiento de cancer de mama localmente avanzado.
WO2014043633A1 (en) 2012-09-17 2014-03-20 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
BR112015010955A2 (pt) 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
BR112015012536A2 (pt) 2012-12-03 2017-07-11 Calithera Biosciences Inc tratamento de câncer com inibidores heterocíclicos da glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
KR20170012562A (ko) 2014-06-13 2017-02-02 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
CN107921031A (zh) * 2015-03-30 2018-04-17 卡利泰拉生物科技公司 给予谷氨酰胺酶抑制剂的方法
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
WO2018039441A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Similar Documents

Publication Publication Date Title
JP2018510884A5 (https=)
RU2597844C2 (ru) Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
CN119317435A (zh) 利用mta协作的prmt5抑制剂的癌症治疗
JP2016502544A5 (https=)
CN103957917A (zh) 用atr抑制剂治疗胰腺癌和非小细胞肺癌
JP2017513908A5 (https=)
JP2019524852A5 (https=)
US20250319186A1 (en) Treatment of canine cancers
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
EP2754441B1 (en) Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives
Vansteenkiste et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model
Nobile et al. A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients
AU2019330954A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
Bruera et al. Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen
WO2016046316A1 (en) Antitumor activity of multi-kinase inhibitors in colorectal cancer
WO2024233874A1 (en) Methods for sequentially administering tas-102 and bcl-2 inhibitor for cancer treatment
Zenke et al. Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged≥ 75 years with squamous-cell lung cancer: TORG1322
JP7530351B2 (ja) 若年哺乳動物の身体における神経芽細胞腫を治療するための方法および組成物
Esmat et al. Next Generation Sequencing (NGS) in Relapsed/Refractory HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Reveals Diverse Genomic Alterations and Potential Targets of Therapy
WO2025106908A1 (en) Treatment of canine cancers
WO2025030049A1 (en) Sequential treatment method for p53-deficient cancer
Dawood American Society of Clinical Oncology 2014: Updates in breast and gastrointestinal cancers
Krishnamurthy et al. Treatment of small cell lung cancer
WO2025193927A1 (en) Use of mithramycin analogue for the treatment of cancer